Dithiocarbamate-Metal Complex Nanoparticles via Blood Serum Protein Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dithiocarbamate-metal complexes, despite showing promising anticancer activity, face challenges due to their low water solubility and narrow therapeutic index, making them difficult to administer effectively in clinical settings.
Innovation Solution
A novel particulate form of dithiocarbamate-metal complexes is developed, specifically a molecular assembly with blood serum proteins, which forms a bioavailable dispersion of nanoparticles that are injectable and substantially free of organic solvents, allowing for improved biological activity and pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dithiocarbamate-metal complexes are used to achieve anticancer activity, then therapeutic effect is improved, but water solubility deteriorates
Solution Approach 1:
The patent introduces blood serum proteins as intermediary carriers that bind to dithiocarbamate-metal complexes, enabling the hydrophobic complexes to be transported in the aqueous blood circulation system. This mediator approach resolves the solubility issue while preserving anticancer activity.
Solution Approach 2:
The patent creates composite particles consisting of dithiocarbamate-metal complexes combined with blood serum proteins. This composite structure allows the hydrophobic complex to be stabilized in aqueous environments through the hydrophilic protein component, achieving both solubility and therapeutic effect.
2Reliability
If dithiocarbamate-metal complexes are used to achieve anticancer activity, then therapeutic effect is improved, but therapeutic index deteriorates
Solution Approach 1:
The patent employs blood serum proteins that can be selectively accumulated in tumor tissues through the enhanced permeability and retention effect, delivering the toxic dithiocarbamate-metal complex preferentially to cancer cells while reducing exposure to healthy tissues, thus improving the therapeutic index.
Solution Approach 2:
The blood serum protein acts as a mediator that controls the release and distribution of the dithiocarbamate-metal complex, enabling targeted delivery to tumor cells and reducing off-target toxicity, thereby improving the therapeutic window.
3Reliability
If dithiocarbamate-metal complexes are formulated for administration, then therapeutic effect is achieved, but formulation capability deteriorates
Solution Approach 1:
The patent uses blood serum proteins as natural formulation carriers that are already present in the biological system, eliminating the need for complex synthetic formulation processes. This approach simplifies manufacturing while ensuring biocompatibility and effective drug delivery.
Solution Approach 2:
The patent leverages the body's own blood serum proteins as the formulation medium, utilizing their natural solubility and transport capabilities to deliver the drug complex, thereby eliminating the need for external formulation systems and simplifying the manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The particulate form enhances the biological activity of dithiocarbamate-metal complexes, enabling their use in cancer treatment and diagnostics, with improved solubility and reduced toxicity, allowing for effective administration and targeted cancer therapy.
Implementation Method 1
The components of a molecular assembly are typically bound together by non-covalent interactions to form the molecular complex
Implementation Method 2
the blood proteins have a considerable capacity to bind to the dithiocarbamate-metal complex that is rapidly formed in the solution and spontaneously assemble into particles
Data Source
AI summary
A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.